William Raich, Ph.D., leader of Finnegan’s biotechnology and pharmaceutical practice group, represents innovative companies developing biologics, pharmaceuticals, medical devices, and diagnostics. As a patent lawyer with a doctorate in cellular and molecular biology, he focuses his practice on patent litigation, pre-litigation counseling, and contentious proceedings at the U.S. Patent and Trademark Office (USPTO), applying his technical expertise and courtroom insight to develop simple, persuasive positions for clients.
Bill has substantial experience with traditional patent litigation in district court and arbitrations, as well as litigating under the Biologics Price Competition and Innovation Act (BPCIA) and litigating Abbreviated New Drug Application (ANDA) cases. He also represents clients before the Patent Trial and Appeal Board (PTAB) of the USPTO, appearing as lead counsel in numerous proceedings. In addition to his contentious work, Bill performs client counseling and opinion work, primarily in areas related to biologics, pharmaceuticals, and DNA sequencing. He has been recognized by LMG Life Sciences as a nominee for General Patent Litigator of the Year in the DC area and as an Intellectual Property: Life Sciences Star. Bill was also named as a DC IP Star by Managing Intellectual Property and a Leading Patent Litigator in the DC area by Intellectual Asset Management.
Bill served at the U.S. Court of Appeals for the Federal Circuit as a law clerk for the Honorable Randall R. Rader and the Honorable Jimmie V. Reyna. He has represented pro bono, including as lead counsel, multiple disabled veterans before the U.S. Court of Appeals for Veteran’s Affairs.
Prior to joining Finnegan, Bill conducted post-doctoral research in molecular biology and neuroscience in the laboratory of Nobel Laureate Eric Kandel at Columbia University. He frequently speaks at conferences on issues such as the developing body of law relating to biologics.
Representative Experience:
- Representing Sarepta Therapeutics in patent litigations involving treatments for Duchenne Muscular Dystrophy
- Representing Eli Lilly in patent litigations involving antibody therapies.
- Represented AbbVie Inc. in Biologics Price Competition and Innovation (BPCIA) litigation related to Humira®
- Successfully represented patent owner in post grant review (PGR) challenge related to Skyrizi®.
Updated Sep 2023
